Patent · US Active

Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (NASH)

US12285464B2 · kind B2 · utility

0Cited by

0References

7Claims

0Family size

Assignees

The Trustees of Columbia University in the City of New York · US
The Brigham and Women's Hospital, Inc. · US

Inventors

Ira Tabas · New York, US
Xiaobo Wang · San Diego, US
Omid C. Farokhzad · Sharon, US
Xiaoding Xu · Malden, US

Key dates

Filing date	Apr 18, 2017
Grant date	Apr 29, 2025
Priority date	—
Expiry date	Aug 27, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to methods and compositions for specifically modulating the Hippo pathway transcription factor TAZ (WWTR1), as a therapeutic target for inhibiting or preventing liver conditions including the progression of steatosis-to-NASH in a patient.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.